Clinical research points to 'future hope' for traumatic brain injury treatmentsRSS Feed

Current scientific research efforts mean that victims of serious traumatic brain injuries (TBIs) may in future have access to improved treatment regimes, it is reported.

US-based pharmaceutical firm BHR Pharma states that there are presently two especially notable clinical trials, which are assessing the safety and effectiveness of progesterone as a neuroprotective agent for treating moderate to severe TBI.

One of the studies is being carried out by BHR Pharma, while the other is a trial being conducted by Emory University.

The firm also saluted the Brain Injury Association of America for its efforts to raise awareness about the dangers and proper treatment of concussions everywhere, from playgrounds to professional sports arenas.

"It is also important to recognise that traumatic brain injuries range from concussions to severe head trauma, such as injuries sustained in traffic accidents - a leading cause of TBI in the world," BHR Pharma added.

BHR Pharma, based in Virginia, was founded in January 2008 and is a wholly-owned subsidiary of Besins Healthcare.

Serious Law, award winning brain injury law firm

FC scans 'can predict seriousness of brain injuries'

23 March 2010

Scientists in the US have said it may be possible to use resting-state functional connectivity (FC) scans to predict the effects of strokes and other brain injuries.The scanning approach was originally...

Read More...

Brain injury list of rugby players 'not workable'

22 March 2010

Plans to create a list of rugby players in New Zealand who have experienced brain injuries have been scrapped, it is reported.New Zealand Rugby Union chiefs considered setting up such a system but concluded...

Read More...

Scientists develop technique to switch off brain cells

19 March 2010

Researchers believe they may have developed a new technique for turning off selected brain cells using light.Scientists from Stanford University, are confident that the technique, which uses optogenetics...

Read More...